We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares
RVLP

Delisted

RVLP was delisted on the 20th of October, 2023.

Back to rankings

66 hedge funds and large institutions have $41.1M invested in RVL Pharmaceuticals plc Ordinary Shares in 2020 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 16

61% more capital invested

Capital invested by funds: $25.6M → $41.1M (+$15.5M)

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

6% more funds holding

Funds holding: 62 → 66 (+4)

Holders
66
Holders Change
+4
Holders Change %
+6.45%
% of All Funds
1.35%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
26
Reduced
16
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
DG Capital Management
New York
+$3.91M
2
BlackRock
BlackRock
New York
+$1.28M
3
GC
Globeflex Capital
California
+$481K
4
EP
Eversept Partners
New York
+$387K
5
JIC
Joel Isaacson & Co
New York
+$220K

Top Sellers

Rank Fund Capital Flow
1
SS
Sunbelt Securities
Texas
-$5.03M
2
SCM
Sio Capital Management
New York
-$1.83M
3
Millennium Management
Millennium Management
New York
-$1.33M
4
WCM
Wedge Capital Management
North Carolina
-$898K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$852K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$9.35M +$1.28M +261,086 +23%
Renaissance Technologies
2
Renaissance Technologies
New York
$6.4M -$349K -71,400 -7%
DCM
3
DG Capital Management
New York
$5.38M +$3.91M +799,208 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.71M +$136K +27,824 +12%
AllianceBernstein
5
AllianceBernstein
Tennessee
$1.7M +$70K +14,300 +6%
Marshall Wace
6
Marshall Wace
United Kingdom
$1.5M -$506K -103,329 -32%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$1.48M +$75.4K +15,400 +8%
State Street
8
State Street
Massachusetts
$1.22M +$79.7K +16,275 +10%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$1.04M -$852K -174,153 -53%
Arrowstreet Capital
10
Arrowstreet Capital
Massachusetts
$976K – – –
AQR Capital Management
11
AQR Capital Management
Connecticut
$860K +$84.9K +17,342 +16%
WCM
12
Wedge Capital Management
North Carolina
$808K -$898K -183,563 -60%
GC
13
Globeflex Capital
California
$661K +$481K +98,247 New
Northern Trust
14
Northern Trust
Illinois
$628K -$178K -36,378 -28%
Charles Schwab
15
Charles Schwab
California
$615K +$128K +26,181 +40%
Russell Investments Group
16
Russell Investments Group
United Kingdom
$564K -$17.7K -3,617 -4%
EP
17
Eversept Partners
New York
$532K +$387K +79,037 New
MAM
18
Martingale Asset Management
Massachusetts
$409K +$29.4K +6,003 +11%
EGM
19
Engineers Gate Manager
New York
$398K +$87.8K +17,937 +44%
Goldman Sachs
20
Goldman Sachs
New York
$387K +$161K +32,985 +135%
AIM
21
Alambic Investment Management
California
$323K -$9.79K -2,000 -4%
PAM
22
Panagora Asset Management
Massachusetts
$318K +$150K +30,669 +184%
JIC
23
Joel Isaacson & Co
New York
$303K +$220K +45,006 New
Prudential Financial
24
Prudential Financial
New Jersey
$233K +$170K +34,667 New
FPS
25
Fieldpoint Private Securities
Connecticut
$226K +$164K +33,583 New
1
2 3 4

RVLP Hedge Fund Activity: Q2 2020 in Review

66 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q2 2020, worth a combined $41.1M — up 61% from $25.6M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new RVLP positions and 10 closed out — a net gain of 5 holders — while 26 added to existing stakes and 16 trimmed.

The largest buyer was DG Capital Management, opening a new position worth an estimated $3.91M. The largest seller was Sunbelt Securities, cutting an estimated $5.03M.

  • 66 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q2 2020, up from 62 in Q1 2020.
  • Funds reported $41.1M of RVL Pharmaceuticals plc Ordinary Shares stock for Q2 2020, up 61% quarter-over-quarter.
  • 15 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q2 2020 and 10 closed out, a net change of +5 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q2 2020 was DG Capital Management, an estimated $3.91M added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q2 2020 was Sunbelt Securities, an estimated $5.03M sold.

Based on aggregated 13F filings for Q2 2020.